(Total Views: 591)
Posted On: 10/10/2023 9:54:38 AM
Post# of 148878
I think that the most annoying thing about this companies communication is that there is no logical sequence of the back and forth between investors and the management. It is one thing that they don't communicate other than PRs and quarterly updates, but the real problem is that there is no question - response ability with management. it is easy to say they can't ay more than what they can put in a PR, but to ask for an increase in share count without explaining why or what the plan is in detail really handicaps investors in there decision. ultimately it does not matter much but it would be nice to have a better back and forth.
wouldn't it be nice if management put out the voting with info about why and where we are at? how about telling investors the status of the clinical hold before the annual meeting? how about giving some idea about the status of future trials or studies? how about explaining why the FDA wanted a protocol submitted and why they wanted key opinions from patients and doctors? It is as if management really is only doing the bare minimum with no idea that investors disserve better.
Antonio made a point that they will communicate better and they have failed. having a QA after the annual meeting is stupid because we have no idea what they are going to tell us in the meeting. i would (as would everyone) ask if the clinical hold is being lifted soon, if they announce it is lifted in the meeting then it is a stupid question. this is a small company with a core groups of dedicated investors, we should all be treated like paulson investors even if they are under an NDA.
I am still angry that the announcement that we are asking for the arbitrator to decide on the Aramex situation and then finding that the process is just starting with discovery and it will be a year before an arbitrator decides anything. was i the only one that thought this was already far down the road and this year it would get resolved? this is nader-like management. all sizzle, no steak. they could have outlined the timeline when they announced this, they chose not to. Management needs to lay out the plan and where things are at at all times. this is a high risk investment and all we are holding on to is how great leronlimab is. Management must wake up and stop keeping us in the dark.
have they completed everything the FDA asked for in the clinical hold?
are they ready with starting studies and trials with a or many partners?
Have they found a short list of CEO's?
when is the rebranding and dose it effect the share count, funding, etc.?
long term investors have endured extreame risk and poor management, we do not disserve a lack of communication where they don't listen and respond. I am sending an email to Antonio and i know i will get no response, that is the problem.
I don't want to get a PR that the hold is lifted and then we sit here wondering what comes after that. will Cytodyn just sit there and wait for the phone to ring from a partner? do we already have a partner? no idea.
wouldn't it be nice if management put out the voting with info about why and where we are at? how about telling investors the status of the clinical hold before the annual meeting? how about giving some idea about the status of future trials or studies? how about explaining why the FDA wanted a protocol submitted and why they wanted key opinions from patients and doctors? It is as if management really is only doing the bare minimum with no idea that investors disserve better.
Antonio made a point that they will communicate better and they have failed. having a QA after the annual meeting is stupid because we have no idea what they are going to tell us in the meeting. i would (as would everyone) ask if the clinical hold is being lifted soon, if they announce it is lifted in the meeting then it is a stupid question. this is a small company with a core groups of dedicated investors, we should all be treated like paulson investors even if they are under an NDA.
I am still angry that the announcement that we are asking for the arbitrator to decide on the Aramex situation and then finding that the process is just starting with discovery and it will be a year before an arbitrator decides anything. was i the only one that thought this was already far down the road and this year it would get resolved? this is nader-like management. all sizzle, no steak. they could have outlined the timeline when they announced this, they chose not to. Management needs to lay out the plan and where things are at at all times. this is a high risk investment and all we are holding on to is how great leronlimab is. Management must wake up and stop keeping us in the dark.
have they completed everything the FDA asked for in the clinical hold?
are they ready with starting studies and trials with a or many partners?
Have they found a short list of CEO's?
when is the rebranding and dose it effect the share count, funding, etc.?
long term investors have endured extreame risk and poor management, we do not disserve a lack of communication where they don't listen and respond. I am sending an email to Antonio and i know i will get no response, that is the problem.
I don't want to get a PR that the hold is lifted and then we sit here wondering what comes after that. will Cytodyn just sit there and wait for the phone to ring from a partner? do we already have a partner? no idea.
(28)
(0)Scroll down for more posts ▼
